SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC

Panelists discuss the most exciting data and studies presented at the San Antonio Breast Cancer Symposium (SABCS) that show promise for improving outcomes in both HR-positive (HR+) and HER2-negative (HER2–) metastatic breast cancer and early-stage triple-negative breast cancer (TNBC), highlighting how precision medicine has enhanced outcomes and the overall patient experience.

EP: 1.NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer

EP: 2.Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data

EP: 3.BRCA Testing in Early-Stage and Metastatic Breast Cancer

EP: 4.OlympiA: Data Updates From SABCS 2024

EP: 5.Role of PARP Inhibitors in Somatic BRCA Mutations and Data Update for PARP Inhibitors

EP: 6.KN-522: Clinical Implications and Insights Into Clinical Practice

EP: 7.Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC

Now Viewing

EP: 8.SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC

Video content above is prompted by the following:

1. Dr. Degen asks Dr. Shatsky: Please highlight the most exciting data or studies from SABCS that you find most promising in terms of improving outcomes in both HR+/HER2– mBC and/or early-stage TNBC. (37:38 – 47:18)
   1. How has precision medicine improved outcomes and the patient experience from your perspective?

Related Videos